BSX vs NVO
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. NVO: A global healthcare leader driving innovations to defeat diabetes, obesity, and other serious chronic diseases.
Side-by-side fundamentals
| Metric | BSX | NVO | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $51.19 | $47.17 | |
| Market cap as of 2026-08-12 | $74.2B | $209.1B | |
| P/E as of 2026-08-12 | 20.00 | 11.61 | NVO lower |
| PEG as of 2026-08-12 | 0.44 | 16.16 | BSX lower |
| Net margin as of 2026-08-12 | +17.5% | +35.4% | NVO higher |
| Gross margin as of 2026-08-12 | +69.8% | +80.7% | NVO higher |
| Operating margin as of 2026-08-12 | +19.8% | +43.1% | NVO higher |
| ROE as of 2026-08-12 | +14.9% | +59.1% | NVO higher |
| ROA as of 2026-08-12 | +8.3% | +21.1% | NVO higher |
| Debt / equity as of 2026-08-12 | 0.43 | 0.63 | BSX lower |
| Revenue growth (YoY) as of 2026-08-12 | +13.5% | +5.6% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +20.4% | NVO higher |
| Dividend yield as of 2026-08-12 | n/a | +3.8% | |
| Beta as of 2026-08-12 | 0.58 | 1.92 | |
| 1-year return as of 2026-08-11 close | -50.2% | -5.4% | NVO higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.